The current study demonstrated two bumetanide-derived inhibitors of AQP1, AqB013 and AqB050, inhibit tube formation in vitro using murine and human endothelial cell lines known to express AQP1, supporting their potential utility as cancer therapeutics. Here, AQP1 is linked to cancer.